Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1

Learn more about:
Related Clinical Trial
Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1 DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1

Official Title

Effects of a 12-week Strength Training Program in Women With Myotonic Dystrophy Type 1

Brief Summary

      20 women with myotonic dystrophy type 1 (DM1) will complete a 12-week lower-limb strength
      training program. The training program consist of 3 series of 6 to 8 maximal repetitions of 5
      different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion.
      Training sessions will be closely supervise and take place twice a week. It is hypothesize
      that the training program will induce muscular hypertrophy despite the genetic defect. The
      training program should also have positive effects on function. The participants will be
      evaluated at baseline, week 6, week 12, month 6 and month 9 to quantify the effects of the
      training program and if these effects will be maintained over time.
    



Study Type

Interventional


Primary Outcome

Changes in maximal isometric muscle strength of the knee extensors

Secondary Outcome

 Changes in maximal isometric muscle strength of the knee flexors

Condition

Myotonic Dystrophy 1

Intervention

Training program

Study Arms / Comparison Groups

 Training program
Description:  12-week strength training program of the lower limbs consisting of 5 different exercises: Leg extension, leg press, hip abduction, squat and plantar flexion. All exercises will be perform between 6 and 8 maximal repetitions.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Other

Estimated Enrollment

20

Start Date

January 1, 2022

Completion Date

December 2022

Primary Completion Date

December 2022

Eligibility Criteria

        Inclusion Criteria:

          -  DM1 diagnosis must be confirmed by genetic analysis;

          -  Women sex, aged between 30 and 65 years old;

          -  Be able to walk without assistance;

          -  Consent of the neurologist must be given to participate in this study;

          -  Must reside in the Saguenay-Lac-St-Jean region;

          -  Subjects must be able to give their consent freely and voluntarily.

        Exclusion Criteria:

          -  Patients with any other form of muscular dystrophy are excluded;

          -  Any contraindication for strenuous exercise or muscle biopsy.
      

Gender

Female

Ages

30 Years - 65 Years

Accepts Healthy Volunteers

No

Contacts

Elise Duchesne, Ph.D, 418-545-5011, [email protected]

Location Countries

Canada

Location Countries

Canada

Administrative Informations


NCT ID

NCT05400629

Organization ID

2022-005


Responsible Party

Sponsor-Investigator

Study Sponsor

Élise Duchesne

Collaborators

 Fondation des maladies rares, CIUSSS du SLSJ

Study Sponsor

Elise Duchesne, Ph.D, Principal Investigator, Université du Québec à Chicoutimi


Verification Date

May 2022